PTC Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
PTC Therapeutics, Inc. (PTCT) reported Net Income (Loss) Available to Common Stockholders, Diluted of $84.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-07-30
- PTC Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $84.45M.
- PTC Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$2.81M, a 100.32% decline year-over-year.
- PTC Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$133.85M.
- PTC Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $16.99M.
- PTC Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was $687.01M.
- PTC Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$363.30M.
- PTC Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$626.60M.
- PTC Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$559.02M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $84.45M 10-Q · filed 2026-07-30 | $82.73M 10-Q · filed 2026-07-30 | -$52.21M derived: sum of 3 quarters · filed 2026-07-30 | -$35.21M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2026-03-31 | -$2.81M 10-Q · filed 2026-05-07 | -$136.66M derived: sum of 2 quarters · filed 2026-05-07 | -$119.67M derived: sum of 3 quarters · filed 2026-05-07 | -$184.52M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-12-31 | -$133.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$116.86M derived: sum of 2 quarters · filed 2026-02-19 | -$181.71M derived: sum of 3 quarters · filed 2026-07-30 | $687.01M 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $16.99M 10-Q · filed 2025-11-04 | -$47.86M derived: sum of 2 quarters · filed 2026-07-30 | $820.87M 10-Q · filed 2025-11-04 | $753.90M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | -$64.85M 10-Q · filed 2026-07-30 | $803.87M 10-Q · filed 2026-07-30 | $736.91M derived: sum of 3 quarters · filed 2026-07-30 | $630.25M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $867.64M 10-Q · filed 2026-05-07 | $801.76M derived: sum of 2 quarters · filed 2026-05-07 | $695.10M derived: sum of 3 quarters · filed 2026-05-07 | $595.92M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$65.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$172.54M derived: sum of 2 quarters · filed 2026-02-19 | -$271.72M derived: sum of 3 quarters · filed 2026-02-19 | -$363.30M 10-K · filed 2026-02-19 | ||
| 2024-09-30 | -$106.65M 10-Q · filed 2025-11-04 | -$205.83M derived: sum of 2 quarters · filed 2025-11-04 | -$297.41M 10-Q · filed 2025-11-04 | -$453.20M derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2024-06-30 | -$99.18M 10-Q · filed 2025-08-07 | -$190.75M 10-Q · filed 2025-08-07 | -$346.55M derived: sum of 3 quarters · filed 2026-02-19 | -$479.52M derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2024-03-31 | -$91.58M 10-Q · filed 2025-05-06 | -$247.37M derived: sum of 2 quarters · filed 2026-02-19 | -$380.34M derived: sum of 3 quarters · filed 2026-02-19 | -$579.22M derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2023-12-31 | -$155.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$288.76M derived: sum of 2 quarters · filed 2026-02-19 | -$487.64M derived: sum of 3 quarters · filed 2026-02-19 | -$626.60M 10-K · filed 2026-02-19 | ||
| 2023-09-30 | -$132.97M 10-Q · filed 2023-10-26 | -$331.85M derived: sum of 2 quarters · filed 2023-10-26 | -$470.81M 10-Q · filed 2023-10-26 | -$641.70M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | -$198.88M 10-Q · filed 2023-08-03 | -$337.84M 10-Q · filed 2023-08-03 | -$508.73M derived: sum of 3 quarters · filed 2025-02-27 | -$618.05M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | -$138.96M 10-Q · filed 2023-04-27 | -$309.85M derived: sum of 2 quarters · filed 2025-02-27 | -$419.16M derived: sum of 3 quarters · filed 2025-02-27 | -$571.25M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | -$170.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$280.20M derived: sum of 2 quarters · filed 2025-02-27 | -$432.29M derived: sum of 3 quarters · filed 2025-02-27 | -$559.02M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | -$109.31M 10-Q · filed 2023-10-26 | -$261.40M derived: sum of 2 quarters · filed 2023-10-26 | -$388.13M 10-Q · filed 2023-10-26 | -$531.39M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | -$152.09M 10-Q · filed 2023-08-03 | -$186.96M 10-Q · filed 2022-08-04 | -$278.81M 10-Q · filed 2023-08-03 | -$313.69M 10-Q · filed 2022-08-04 | -$422.08M derived: sum of 3 quarters · filed 2024-02-29 | -$555.70M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$126.73M 10-Q · filed 2023-04-27 | -$269.99M derived: sum of 2 quarters · filed 2024-02-29 | -$403.62M derived: sum of 3 quarters · filed 2024-02-29 | -$521.99M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | -$143.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$276.89M derived: sum of 2 quarters · filed 2024-02-29 | -$395.26M derived: sum of 3 quarters · filed 2024-02-29 | -$523.90M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | -$133.62M 10-Q · filed 2022-10-27 | -$251.99M derived: sum of 2 quarters · filed 2022-10-27 | -$380.64M 10-Q · filed 2022-10-27 | |||
| 2021-06-30 | -$118.37M 10-Q · filed 2022-08-04 | -$247.01M 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | -$128.64M 10-Q · filed 2022-05-03 | |||||
| 2020-12-31 | -$438.16M 10-K · filed 2023-02-21 | |||||
| 2019-12-31 | -$251.58M 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |